Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: NUMIF )

0.0234 UNCHANGED
Streaming Delayed Price Updated: 3:44 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NUMIF

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Via Benzinga
Exposures Product Safety
Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), announced on Thursday its third quarter financial results for the three months ended May 31, 2024."In... 
Via Benzinga
Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
Psychedelics-focused mental healthcare company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) plans to take over MedBright AI Investments Inc. (CSE: MBA).The proposed transaction comes as... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Via Benzinga
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Via Benzinga
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Via Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Via Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers. 
Via InvestorPlace
Exposures Product Safety
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
Psychedelics mental healthcare company Numinus Wellness (OTCQX: NUMIF) posted its financial results for the three months ended Nov. 30, 2023. Q1 numbers show: 
Via Benzinga
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health... 
Via Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
Psychedelic therapy clinic provider Numinus Wellness (TSX:NUMI) (OTC: NUMIF) announced  
Via Benzinga
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval.  
Via Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice... 
Via Benzinga
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve. 
Via Benzinga
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud 
Via Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for... 
Via Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network
On this new Psychedelic Series Podcast, TDR Founder Shadd Dales spoke with Payton Nyquvest, CEO of Numinus Wellness Inc. (OTC: NUMIF). 
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
Numinus Q2 2023: 581% Revenue Growth, 820% In Gross Profit And Strong Cash Position
Psychedelics mental healthcare company Numinus Wellness Inc. (OTCQX: NUMIF) announced its financial results for the three and six months ended Feb. 28, 2023. Q2 numbers show: Total cash of $14.7... 
Via Benzinga
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
“Investing in real estate can help expand experiential medicines like ketamine and MDMA for treating PTSD and build infrastructure for upcoming FDA-approved therapies,” said Daniel Carcillo, founder... 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.